Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J Landsburg,Matthew J Frigault,Zhen-Huan Hu,Samantha Jaglowski,Frederick L Locke,Christine Ho,Miguel-Angel Perales,Caron Jacobson,Brian T Hill,Stephen Ronan Foley,Peter A Riedell,Ranjan Tiwari,Aisha Masood,Stephen Lim,Marta Majdan,Marcelo C Pasquini,Cameron J Turtle

doi:10.1182/blood-2021-146397

Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J Landsburg, Matthew J Frigault + Show 15 more

Open Access

https://doi.org/10.1182/blood-2021-146397

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 9

Affiliation: Moffitt Cancer Center, Roswell Park Cancer Institute, Medical College of Wisconsin, Cleveland Clinic, Tris Pharma (United States), Dana-Farber Cancer Institute, University of Washington, Juravinski Hospital, The Ohio State University, Memorial Sloan Kettering Cancer Center, University of Chicago, Novartis (India), Novartis (Canada), University of Pennsylvania, Massachusetts General Hospital

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Full Text